OPTI!!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another day of the .08 wall
Another bottom day....grrr....
Wth was that drop about,
What's happened? What I miss?
The lows should be non existent.
The lows should be .10s
I really don't get how the PPS is not up to .15+
USRM is days or weeks from RMAT approval which will soar revenues in US
Now even advertising Myocell.
Even notwithstanding, revenues have consistently and substantially increased over the last year, and all toxic convertible debt has been paid off.
Not to mention the obvious elephant in the room...stem cell medicine and therapies (i.e regenerative medicine) are the future of medicine and USRM has products and therapies (Myocell, Vetbiologics, etc.) on the upper, if not the top, of the field.
The PPS has.....yes look at the chart....substantially increased, in a reasonably argued stair step pattern of late, with gradual higher highs and higher lows, with the small exception of the drop in the last 2-3 trading sessions.
This drop can clearly be contributed solely to market manipulation, low volume, and the CEO vague blog as to RMAT approval date.
The low volume on no-news days is contributed to most shares being consolidated and held by longs.
The RMAT approval date was presumed by many in here and posted about so many times, that it reached a consensus that was not based in reality or substantiated in evidence.
The CEO blog, as vague as it is as far as dates, clearly states that the ball is now in the FDA hands, acknowledging the receipt of the supplemental requested material.
Thus means RMAT approval, which little can deny was tailor made for USRM, is on track, and will likely be approved anyday.
ANY nonsense about .06,s and .07s is just that IMHO nonsense. Furthermore the nonsense that RMAT approval is reflective in the PPS already is nonsense based on any reasonable calculation of the value of the company. At its current revenue/debt, and taking into its potential, there can be little doubt that the PPS of .10-.15 is right where it belongs. Anything less than that is bargain basement.
When RMAT is approved, the revenue streams are easily and immediately increased 10-30 fold, and as the company expands, could and will exponentially increase unless the more likely buyout occurs.
USRM, long and strong.
based on the news article...shouldn't this be dropping like a stone right now???
Wow...then this ain't going anywhere.
Then explain why it just seems to constantly go down
Please read people
CNA Finance Article
CytRx Corporation (CYTR) Stock: Where To Next?
InvestingBiotechBreaking NewsJun 5, 2017
CytRx Corporation (NASDAQ: CYTR) is having a rough start to the trading session in the pre-market hours today. The declines come after the company offered multiple presentations at the 2017 ASCO meeting with regard to aldoxorubicin. While there was a concerning statistic in one of the two presentations, the data was positive overall. At the moment (8:59), CYTR is trading at $0.68 per share after a loss of $0.14 per share or 17.07% thus far today.
This Is Likely A Buying Opportunity
The great Warren Buffet has said that the time to buy is when fear is high. In this particular case, I believe he is correct. You see, as mentioned above, CytRx Corporation released data with regard to aldoxorubicin at the 2017 ASCO meeting. While Adam Feuerstein and others are focusing on the one bit of news that wasn't great, there is plenty to be excited about.
First and foremost, let's address the elephant in the room. In the first presentation offered, CYTR provided Phase 3 aldoxorubicin data in the treatment of soft tissue sarcoma. The concern here is that the treatment showed no difference in overall survival when compared to the investigator's choice of therapy. This one bit of news is causing declines while investors seem to be ignoring the rest of the data.
When it comes to aldoxorubicin, while the Phase 3 data did not show an extension of overall survival, there was extended median progression-free survival, no signs of alopecia, and the treatment was relatively well-tolerated. However, that wasn't the only positive news.
Ultimately, the most positive data came from the company's combination study. In this study, patients were given aldoxorubicin along with 14 continuous days of infusion of ifosfamide/Mesna. This data proved to be overwhelmingly positive. First and foremost, CYTR reported 73% tumor reduction following 2 cycles of the combination treatment. The company also reported significant calcification and over 20% tumor reduction following 14 cycles of aldoxorubicin and 6 cycles of ifosfamide/Mesna. Also, among the patients who proceeded with post-treatment surgery, half of the patients had tumor necrosis of 90% or more and 9 of 10 had tumor necrosis of 70% or more.
Considering the data above, the declines in the stock are likely a reaction to various reports in which authors are only focusing on the negative. The truth is that the negative isn't necessarily bad news. Sure OFS did not increase compared to the investigator's choice, but at the end of the day, there was plenty of positive news, especially on the combination treatment side. However, you don't have to take my word for it, just look at the presentations offered by CYTR for yourself! As a result, my view of the company remains unchanged.
Another day on this side of th e .083 wall.
Good article.
Unfortunately presumes people read
3 month and 6 month chart telling diff story
You would think a post or PR to keep shareholders apprised would be done.
Is this company even in business/doing anything anymore?
Actually undervalued. Especially given its potential
Been in 4 six months already
Holding strong. 0 sold
Picked up a few more
All true. ..excellent post
Everyone should see this video!!
Have you checked the scoreboard?
USRM recovered in 2 days. I think that beats any previous record.
Bye weak impatience. ..Hello dollar signs
Have to respectfully disagree ( as I know you are a strong long and strong poster)
Basing this stock solely on its quarterlies is not conducive since in doing so it fails to account for potential and the immediacy of the benefit of RMAT approval.
Aside from this I agree with everything you've said (that I've read) to date.
Excellent post
Respectfully disagree.
The safest assumption is that the FDA could make decision at any time, and USRM could announce any day from now until the latest being early/mid July.
Given acknowledgement in "May", one could assume at least a 2 week delay in information, which likely means FDA received the supplement information anywhere from mid April to mid May.
I agree that FDA may not take the full 60 days, but again...speed of govt.
Moving at the speed of government.
I for one am not surprised at all that the FDA, like any other bureaucratic agency works at a snails pace.
CEO BLOG POST BREAKDOWN (should be stickied)
Dear shareholders and friends,
May has been an exciting month with diverse accomplishments for U.S. Stem Cell, Inc. Our revenues continue to trend positive and all financial indicators are moving in the right direction. We have also helped open the first Stem Cell Centers of Excellence and the first patient has successfully been treated.
CLEARLY REVENUES HAVE INCREASED. CONVERTIBLE DEBT PAID OFF!!
CLINIC OPEN!!! PATIENT TREATED.....SUCCESSFULLY!!! WOOHOO!!
We are very pleased with the 2017 improvements in operations and balance sheet performance. We are progressing with our principal strategic business initiatives which include growing top line revenues and pursuing new business opportunities for exponential growth.
BALANCE SHEET AGAIN...REVENUE SUBSTANTIAL INCREASE... CAN YOU IMAGINE WHEN RMAT ALLOWS FOR SALES INCREASES?
Here is a summary of the excellent financial figures for Q1 of 2017 recently reported:
Revenue up by 62% from $710,000 in Q1 2016 to $1.15M in Q1 2017
Gross profit up by 45.6% from $556,000 in Q1 2016 to $810,000 in Q1 2017
Cash Flow is positive Q1 2017 at $268,000 compared to Q1 2016 at ($62,000)
All debt-to-equity convertible notes have been either fully paid or converted as of March 31, 2017.
(AGAIN...WOOHOO!!)
The first Stem Cell Centers of Excellence opened its doors and successfully treated its first patient this month in the beautiful city of South Miami, Florida. The center is the first of ten we plan to help open in key metropolitan areas over the next three years. The clinics will deliver patient-specific cellular treatments to patients suffering from degenerative diseases or injury.
Learn more about Stem Cell Centers of Excellence: www.stemcellcoe.com
At the beginning of the year, we applied for the FDA’s new Regenerative Medicine Advanced Therapy (RMAT) designation for our MyoCell™ product. In March 2017, the FDA reinstated our IND (MARVEL trial) to active status. In May, the FDA acknowledged that they received our additional information and are still in the process of reviewing our application for RMAT. Please note the FDA takes up to 60 days to review information submitted.
OK...SO HERE'S THE RUB. OUR CEO IS A LITTLE VAGUE ON DATES, BUT EVERYTHING IS CLEARLY STILL ON TRACK. AND NO NEW REQUEST FOR ADDITIONAL INFORMATION MENTIONED. RMAT CAN BE APPROVED ANYDAY...WITHOUT WARNING...AND UP UP UP WE GO!
Read more here: https://goo.gl/K5pvvt
Our Chief Scientific Officer, Kristin Comella, had a chance to speak at the Paleo F(x) Conference in Austin, Texas a few days ago. The conference features speakers on a variety of topics, including holistic wellness, health, nutrition, fitness, sustainability, and self-development. Kristin will also be speaking at the prestigious RAAD Fest in San Diego, as well as the Cell Surgical Network in Los Angeles this weekend.
At U.S. Stem Cell, Inc. our goal is to innovate and develop new therapies and protocols to expand the reach of regenerative medicine and bring our therapies to patients around the world. We are well on track to help meet our goals.
Warmest regards,
Mike Tomas
President and CEO
AGAIN, IF WE COULD GET CLARIFICATION ON FDA COMMUNICATIONS AND DATES...WE CAN ALL STOP WORRYING.
BOTTOM LINE...STRONG COMPANY, STRENGTHENED FINANCIALS, MORE POTENTIAL THAN MOST, IF NOT, ALL OTC's.
June 13 is mine bday. Hopefully good year for me
Exactly
Again, I repeat my question.. why can we not get clarification as to the CEO blog, as to dates, and what is meant by vague statements.??
All good news, other than the delay in RMAT.
Can stop worrying on the daily now..
Why all the secrecy?
Just F ING tell us already
Slap it!!!
I can feel news coming...
And to red we close.
Ask to .11 min
Power hour. Raise the asks.
No more cheapies. News could come in an hour and 5 minutes
No reason for this